Henlius Biotech's Trial of Macular Degeneration Drug Meets Primary Endpoint

MT Newswires Live06-16

Shanghai Henlius Biotech's (HKG:2696) phase 3 study of HLX04-O in patients with wet age-related macular degeneration met its primary study endpoint, according to a Tuesday filing with the Hong Kong bourse.

HLX04-O had a good safety profile, with similar overall, ocular and non-ocular safety results compared to ranibizumab.

The drug is a new ophthalmic preparation product developed based on Hanbeitai, the exclusive rights of which for ophthalmic treatment and therapy worldwide have been granted by the company to Essex Bio-Technology (HKG:1061) and Zhuhai Essex Bio-Pharmaceutical.

The company has an agreement to co-develop the relevant product with Essex Bio-Technology.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2643756031?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-16 18:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2643756031","market":"sg","top_or_hot":-1,"title":"Henlius Biotech's Trial of Macular Degeneration Drug Meets Primary Endpoint","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/SGBCF\">Shanghai Henlius Biotech</a>'s (HKG:2696) phase 3 study of HLX04-O in patients with wet age-related macular degeneration met its primary study endpoint, according to a Tuesday filing with the Hong Kong bourse.</p><p>HLX04-O had a good safety profile, with similar overall, ocular and non-ocular safety results compared to ranibizumab.</p><p>The drug is a new ophthalmic preparation product developed based on Hanbeitai, the exclusive rights of which for ophthalmic treatment and therapy worldwide have been granted by the company to <a href=\"https://laohu8.com/S/01061\">Essex Bio-Tech</a>nology (HKG:1061) and Zhuhai Essex Bio-Pharmaceutical.</p><p>The company has an agreement to co-develop the relevant product with Essex Bio-Technology.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Henlius Biotech's Trial of Macular Degeneration Drug Meets Primary Endpoint</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHenlius Biotech's Trial of Macular Degeneration Drug Meets Primary Endpoint\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-16 18:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/SGBCF\">Shanghai Henlius Biotech</a>'s (HKG:2696) phase 3 study of HLX04-O in patients with wet age-related macular degeneration met its primary study endpoint, according to a Tuesday filing with the Hong Kong bourse.</p><p>HLX04-O had a good safety profile, with similar overall, ocular and non-ocular safety results compared to ranibizumab.</p><p>The drug is a new ophthalmic preparation product developed based on Hanbeitai, the exclusive rights of which for ophthalmic treatment and therapy worldwide have been granted by the company to <a href=\"https://laohu8.com/S/01061\">Essex Bio-Tech</a>nology (HKG:1061) and Zhuhai Essex Bio-Pharmaceutical.</p><p>The company has an agreement to co-develop the relevant product with Essex Bio-Technology.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HK0000320264.USD","symbol_name":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) ACC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2643756031","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2643756031","pubTimestamp":1781606772,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Shanghai Henlius Biotech's  phase 3 study of HLX04-O in patients with wet age-related macular degeneration met its primary study endpoint, according to a Tuesday filing with the Hong Kong bourse.HLX04-O had a good safety profile, with similar overall, ocular and non-ocular safety results compared to ranibizumab.The drug is a new ophthalmic preparation product developed based on Hanbeitai, the exclusive rights of which for ophthalmic treatment and therapy worldwide have been granted by the company to Essex Bio-Technology  and Zhuhai Essex Bio-Pharmaceutical.The company has an agreement to co-develop the relevant product with Essex Bio-Technology.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HK0000320264.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) ACC","01061":"亿胜生物科技","02696":"复宏汉霖","HK0000306685.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) INC","HK0000320223.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) ACC","BK1161":"生物科技","BK4588":"碎股","XBI":"SPDR S&P Biotech ETF","BK4585":"ETF&股票定投概念","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","HK0000306701.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) INC","BK4581":"高盛持仓"},"translate_title":"复宏汉霖生物黄斑变性药物试验达到主要终点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02696":1,"XBI":1.5,"01061":1},"content_text":"Shanghai Henlius Biotech's (HKG:2696) phase 3 study of HLX04-O in patients with wet age-related macular degeneration met its primary study endpoint, according to a Tuesday filing with the Hong Kong bourse.HLX04-O had a good safety profile, with similar overall, ocular and non-ocular safety results compared to ranibizumab.The drug is a new ophthalmic preparation product developed based on Hanbeitai, the exclusive rights of which for ophthalmic treatment and therapy worldwide have been granted by the company to Essex Bio-Technology (HKG:1061) and Zhuhai Essex Bio-Pharmaceutical.The company has an agreement to co-develop the relevant product with Essex Bio-Technology.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2643756031","isCrawlerRequest":true}